Time-restricted Eating in Patients With Moderate Chronic Kidney Disease and Albuminuria: A Pilot Randomized, Open-label, Double-arm Trial (TRECK)

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Chronic kidney disease (CKD) affects approximately 12 to 15% of adults worldwide, with an increasing incidence expected. Major causes include diabetic nephropathy, hypertension, and various glomerulonephritis. Proteinuria is a key factor in identifying and assessing the risk of CKD progression. The precise pathophysiology of CKD is not fully understood, but recent research highlights metabolic alterations, particularly in lipid and glucose metabolism. CKD progression is influenced by diet, as evidenced by recent studies. Interventions such as the ketogenic diet and time-restricted feeding show promising results in improving metabolism and may have beneficial effects on CKD. Our study aims to evaluate the impact of time-restricted eating (TRE) on proteinuria, the decline in glomerular filtration rate, and weight loss in patients with moderate CKD with albuminuria (KDIGO stage 2-3). This will allow us to better understand the efficacy of this dietary approach tailored to the individual habits of participants. The primary outcome measure will be albuminuria before and after the 12-week intervention. Secondary outcome measures will include the impact of fasting on blood pressure as assessed by 24-hour ambulatory monitoring, body composition evaluated by DXA and BIA, continuous glucose monitoring, and blood hormone profiles. Additionally, the feasibility and safety of TRE in this population will be assessed.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Clinical criteria

‣ Adult men and women

⁃ Chronic Kidney Disease with KDIGO stage G2 and G3 defined by a Glomerular Filtration Rate between 30 and 90 mL/min/1.73m2

⁃ Albuminuria stage A2 or A3, but without nephrotic-range proteinuria: 3 to 200 mg/mmol

⁃ Body mass index 18-40 kg/m2

⁃ Eating window of 12 hours (self-reported and measured during the run-in phase)

• Study-related criteria

‣ Able to give informed consent and follow the study procedures for the entire duration

⁃ Confident use of a smartphone compatible with the MyFoodRepo app (iOS, Android) and able to take regular pictures of food/drinks

Locations
Other Locations
Switzerland
University Hospital, Geneva
RECRUITING
Geneva
Contact Information
Primary
Delal Dalga, MD, PhD
delal.dalga@unige.ch
+41-22-3723311
Backup
Anna Faivre, MD, PhD
anna.faivre@hug.ch
+41-79-5534361
Time Frame
Start Date: 2024-12-04
Estimated Completion Date: 2027-12
Participants
Target number of participants: 50
Treatments
Experimental: Time-restricted eating
Active_comparator: Active control
Sponsors
Leads: de Seigneux Sophie
Collaborators: University Hospital, Geneva

This content was sourced from clinicaltrials.gov